January 6, 2026, Chiyoda-ku, Tokyo — PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jun Minamitani) has successfully developed a novel synthetic peptide called “IL-15 alternative peptide” which is functionally equivalent to recombinant interleukin 15 (IL-15). This product will be on the market in December 2025. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
Novo Nordisk Ends $598M Heartseed Partnership to Refocus Strategic Priorities
Sadly, Novo Nordisk has ended its $598 million collaboration with Tokyo-based biotech Heartseed, marking a major shift in its approach to regenerative medicine and iPSCs, specifically. The cancelled partnership, originally launched in 2021, was focused on developing an allogeneic induced pluripotent stem cell (iPSC)-derived therapy for heart failure called “HS-001”.
Novo’s decision to terminate the deal, announced by Heartseed in a securities filing this week, was attributed to “strategic reviews and business shifts” under the company’s new CEO, Mike Doustdar. The move ends a four-year partnership that once represented a bold leap into regenerative medicine for Novo Nordisk. [Read more…]
Trailhead Biosystems Puts iPSCs on a New Path
Biotech founder and CEO Jan Jensen has never been one for following the beaten track. As a young scientist studying the formation of insulin-producing pancreatic cells, Jensen questioned the prevailing view that these cells descended from neuroectoderm. His pancreatic embryonic tissue studies told him otherwise: insulin-producing pancreatic cells originate from within the pancreas itself. Jensen’s hypothesis, now the accepted view, and his further studies made him the first developmental biologist at Novo Nordisk, at a time when the world’s largest insulin producer had little interest in cell-based therapy. Now, 20 years later, Novo Nordisk is at the forefront of cell-based Type I Diabetes research. [Read more…]
Curi Bio Secures $10M Series B to Scale Human-Relevant iPSC-Based Preclinical Platforms and Advanced Data Analysis for Drug Discovery
Financing led by DreamCIS will accelerate and expand development of the company’s industry-leading integrated platform, combining human iPSC-derived cells, advanced biosystems, and functional data analysis to de-risk and accelerate therapeutic development.
SEATTLE — Curi Bio, a leader in delivering human-relevant functional data for drug discovery and development, today announced the close of a $10 million Series B financing round. The round was led by DreamCIS, the leading contract research organization based in Seoul, South Korea, offering comprehensive services for clinical research and regulatory affairs. This strategic partnership is poised to accelerate the translation of Curi Bio’s human-relevant platforms into global clinical success. [Read more…]
Patient Enrolment Complete in Phase 2 aGvHD Clinical Trial
Announcement Highlights:
- Patient enrolment has been completed in Cynata’s Phase 2 clinical trial of CYP-001 in acute graft versus host disease.
- The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus CYP-001, or steroids plus placebo.
- Primary evaluation period expected to complete in March 2026, with results in June 2026.
- CYP-001 has potential to address a major unmet need for the treatment of aGvHD, a life-threatening condition.
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 145
- Next Page »